Module 3

Objectives

The Nurse Learning Module will provide an overview of two common indolent lymphoma subtypes, including follicular lymphoma and marginal zone lymphoma. They will also discuss the current standard management for patients in Australia.

The module will discuss the nursing management for the patient with indolent lymphoma, including case studies to reflect on your practice.

At the completion of module three participants will have an in-depth knowledge of indolent lymphoma including follicular lymphoma and mantle cell lymphoma. Participants will understand;

  • The definition of indolent lymphoma
  • How indolent lymphomas differ from aggressive lymphomas
  • The different types of indolent lymphoma
  • Follicular lymphoma – presentation and management 
  • Mantle cell lymphoma – presentation and management
  • New therapies and clinical trials for indolent lymphoma
  • Nursing implications of caring for an indolent lymphoma patient

Module three presentations

Part 1: Indolent lymphoma: current and emerging management
Professor Chan Cheah – Consultant Haematologist, Sir Charles Gairdner Hospital & Hollywood Private Hospital, Perth, WA

Professor Chan Cheah is a Haematologist and Clinical Researcher at Breakthrough Haematology, Sir Charles Gairdner Hospital, Hollywood Private Hospital, and the University of Western Australia (UWA). 

He graduated in Medicine from the UWA in 2003 and completed training at Fremantle Hospital and Peter MacCallum Cancer Centre (PMCC) in Melbourne, followed by Fellowships at Peter MacCallum Cancer Centre and MD Anderson Cancer Centre (Houston, Texas, USA).

Prof Cheah is the clinical lead for lymphoma at Sir Charles Gairdner Hospital and Director of the WA Lymphoma Centre of Research Excellence. 

His research interests are novel drug therapies and prevention of CNS relapse in lymphomas. He has authored >70 peer-reviewed publications, 6 book chapters, attracted >3 million dollars in competitive grant funding and reviews for major journals in the field. Dr Cheah and is an internationally recognised lymphoma researcher.

  • Prof Cheah is a clinical Professor of Medicine at the University of WA, 
  • Chair of the Australian Lymphoma Alliance
  • Founder of Blood Cancer Research WA
  • Medical committee member for Lymphoma Australia

Part 2: Nursing management of the patient with indolent lymphoma
Ron Middleton – Haematology Nurse Coordinator, Toowoomba Hospital, Toowoomba, QLD

Ron Middleton has a very impressive career where he has been a registered nurse for almost 35 years and worked in malignant haematology for most of that time. Ron has achieved his training at the Royal Brisbane & Women’s hospital and the University of Southern Queensland.

Ron has an impressive CV having worked in a number of clinical areas and nursing roles including the Haematology & bone marrow transplant unit – 1987 – 2013 (RBWH) and the Clinical nurse consultant for haematology & bone marrow transplant. Ron is currently the Haematology Cancer Care Coordinator & CNC at Toowoomba Hospital since 2013 in Queensland

He has also been a lecturer at the Queensland Institute of technology. Ron has co-authored on a number of peer reviewed publications. He is involved member within a number of national and international professional organisations including the current QLD branch deputy chairperson for CNSA

He has a number of special interests including education, mentoring and developing haematology & bone marrow clinical nursing expertise.

Post assessment

To be eligible for a certificate of attendance, you need to complete a short assessment. The certificate will be emailed to you shortly after you have submitted the assessment.

Evaluation Survey

Please complete our short evaluation survey (if you haven’t done so already) to let us know if we met your expectations and ensure we meet your future learning needs.

Further reading and resources

Support and information

Share This

Contact Lymphoma Australia Today!

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.